SB-497115-GR is primarily used in pharmaceutical research and development, particularly in the study of thrombopoietin receptor agonists. It plays a significant role in investigating treatments for thrombocytopenia, a condition characterized by abnormally low levels of platelets in the blood. Researchers utilize this compound to explore its potential in stimulating platelet production, which is crucial for patients undergoing chemotherapy or those with immune thrombocytopenia. Its application extends to preclinical studies, where it helps in understanding the mechanisms of platelet regulation and the development of novel therapeutic agents. Additionally, SB-497115-GR is employed in experimental models to assess efficacy and safety profiles, contributing to advancements in hematology and oncology research.